![](/sites/default/files/styles/medium/public/oembed_thumbnails/4stie-Khp6RcCM28w6Tw6jrtkkKFUaFOSMkg13R9wGw.jpg?itok=l-Ji4gTS)
Dr. Rick Bright has extensive experience in global public health, working with the U.S. Center for Disease Control and Prevention (CDC), PATH and the private sector making key advancements in vaccine and therapeutic developments for influenza viruses with pandemic potential and new vaccine, treatment and testing technologies. He has served as a key advisor in a number of roles, including in the development of the Coalition for Epidemic Preparedness Innovations (CEPI), the WHO Research and Development Blueprint for Action to Prevent Epidemics, the WHO Global Action Plan for Influenza vaccines, and the National Academies of Sciences, Engineering & Medicine Forum on Microbial Threats. He led and coordinated the U.S. and global medical countermeasure development for the 2014 MERS outbreak (another coronavirus) and served as Incident Commander for medical countermeasure response against the Zika virus in 2016. Most recently Bright served the U.S. Department of Health and Human Services as the Deputy Assistant Secretary for Preparedness and Response and Director of the esteemed Biomedical Advanced Research and Development Authority (BARDA). Bright resigned from government service in protest over the Trump administration's approach to handling the Covid-19 pandemic, specifically over the level of political interference over science and the spread of inaccurate information that he said was 'dangerous, reckless and causing lives to be lost'.